Akèy › Kansè poumon selil ti › Washington › Seattle
Etid klinik pou Kansè poumon selil ti nan Seattle, WA
10 etid pou Kansè poumon selil ti ap chèche patisipan nan sit nan ak bò kote Seattle (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- University of Washington, Fred Hutchinson Cancer Center, Seattle
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Ap rekriteFaz 1
- Fred Hutchinson Cancer Research Center, Seattle
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
- University of Washington Fred Hutchinson, Seattle
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
Ap rekriteFaz 1/2
- Fred Hutchinson Cancer Center, Seattle
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Ap rekriteFaz 3
- Swedish Medical Center, Seattle
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Ap rekriteFaz 1/2
- Avenzo Therapeutics Recruiting Site, Seattle
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Ap rekriteFaz 1/2
- Fred Hutch Cancer Research, Seattle
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Ap rekriteFaz 1/2
- Fred Hutch Cancer Center, Seattle
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Ap rekriteFaz 1/2
- Swedish Cancer Institute, Seattle
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Ap rekriteFaz 1
- Swedish Cancer Institute, Seattle
Etid Kansè poumon selil ti nan lòt vil
- Houston, TX26 etid
- Arlington, VA23 etid
- Boston, MA21 etid
- New York City, NY21 etid
- Nashville, TN20 etid
- Los Angeles, CA20 etid
- Orlando, FL15 etid
- Dallas, TX13 etid
- St. Louis, MO13 etid
- Cleveland, OH13 etid
- Detroit, MI12 etid
- Chicago, IL12 etid
Lòt etid nan Seattle
- Kansè Poumon ki pa ti selil53 etid
- Kansè (tout kalite)49 etid
- Kansè pwostat42 etid
- Leksemi mieloïd egi40 etid
- Kansè nan tete39 etid
- Kansè Metastatik39 etid
- Kansè kolorektal34 etid
- Kansè poumon33 etid
- Kansè ovè30 etid
- Myelom Miltip22 etid
- Sendwòm myelodisplastik21 etid
- Leksemi limfoblastik egi21 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.